Context Therapeutics Inc. Common Stock (CNTX) Stock Price
CNTXStock
$0.44−47.88%52W
Market Cap$40.00M
P/E—
PEG Ratio—
Div yield—
Beta1.75
CNTX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-91.19%
Price vs S&P 500 (4W)-24.25%
VGM Score12.83
CNTX Earnings Surprise History
Q2 25-0.09est. -0.05
Q3 25-0.10est. -0.09
Q4 25-0.14est. -0.11
Q1 26-0.09est. -0.12
Q2 26-0.15est. -0.09
CNTX Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.19
4.20
4.19
4.19
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CNTXContext Therapeutics Inc. Common Stock | — | — | F | $0.44 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Context Therapeutics Inc. Common Stock
Context Therapeutics is a clinical-stage biopharmaceutical company developing targeted immunotherapies for solid tumors, with an initial focus on hormone-dependent cancers in women, including breast, ovarian, and endometrial cancer. Its lead program, CTIM-76, is a bispecific antibody that redirects T-cells to attack cancer cells expressing CLDN6, combining immune activation with tumor-specific targeting. The company aims to deliver efficacy while minimizing off-target effects through this precision approach.